Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2020 Earnings Conference Call - Final Transcript
May 07, 2020 • 04:30 pm ET
Ladies and gentlemen, thank you for standing by. And welcome to the Syndax First Quarter 2020 Conference Call. [Operator Instructions] After the speaker presentation, there will be a question-and-answer session. [Operator Instructions]
I would now like to hand the conference over to your speaker today, Melissa Forst with Argot Partners. Thank you. Please go ahead now.
Thank you, operator. Welcome. And thank you to those of you joining us on the line and the webcast this afternoon for a review of Syndax' first quarter 2020 financial and operating results.
I'm Melissa Forst of Argot Partners and with me this afternoon to discuss the results and provide an update on the Company's progress are Dr. Briggs Morrison, Chief Executive Officer; and Rick Shea, Chief Financial Officer. Also joining us on the call for the question-and-answer session is Michael Metzger, President and COO; Dr. Michael Meyers, Chief Medical Officer; and Dr. Peter Ordentlich, Chief Scientific Officer.
This call is being accompanied by a slide deck that has been posted to the company's website, so I'd ask that you please turn to the forward-looking statements on Slide 2.
Before we begin, I'd like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the Risk Factors section in the company's most recent quarterly report on Form 10-Q, as well as other reports filed with the SEC. Forward-looking statements represent the company's views as of today, May 7, only. A replay of the call will be available on the company's website at syndax.com after the call.
And with that, I'm pleased to turn the call over to Dr. Briggs Morrison, Chief Executive Officer.
Briggs W. Morrison
Thank you very much, Melissa. And thank you to everyone joining us on today's call and webcast. Before we get started, I'd like to take a moment to acknowledge that we are actively monitoring the ongoing COVID-19 pandemic to assess any potential impacts to our business. Our number one priority is, of course, the health and safety of our employees, as well as the patients and medical professionals involved in our ongoing clinical programs. At this time, we do not anticipate any interruption or delays to our ongoing clinical programs nor do we expect any impact on our financial guidance. We will continue to monitor the evolving situation, and we'll provide updates as necessary.
Let us now turn to Slide 3, which provides a high-level summary of our current corporate priorities as we strive to realize a future in, which people with cancer live longer and better than ever before. As we had anticipated, 2020 is turning out to be a tremendously exciting and transformative year for our company. Since our last call in March of this year, we have presented the first clinical evidence that inhibition of